Reporting OR (ROR) of COVID-19 vaccines and all other vaccines (primary analysis)
| Type of analysis | ILD cases | Non-cases | ROR (95% CI) |
| Primary analysis (cases: 679, non-cases: 6790) | |||
| The other vaccines | 53 (7.8) | 459 (6.8) | Reference |
| COVID-19 vaccines | 626 (92.2) | 6331 (93.2) | 0.86 (0.64 to 1.15) |
| mRNA COVID-19 vaccines | 448 (66.0) | 3912 (57.6) | 0.99 (0.73 to 1.34) |
| Tozinameran | 373 (58.9) | 3282 (54.4) | 0.98 (0.73 to 1.33) |
| Elasomeran | 73 (11.5) | 611 (10.1) | 1.04 (0.71 to 1.50) |
| Viral vector COVID-19 vaccines | 137 (20.2) | 1718 (25.3) | 0.69 (0.50 to 0.96) |
| Vaxzevria | 126 (19.9) | 1461 (24.2) | 0.75 (0.53 to 1.05) |
| Gam-COVID-Vac | 0 (0.0) | 2 (0.0) | NC |
| Ad26.COV2.S | 8 (1.3) | 220 (3.6) | 0.32 (0.15 to 0.67) |
| Protein-based COVID-19 vaccines | 0 (0.0) | 3 (0.0) | NC |
| NVX-CoV2373 | 0 (0.0) | 3 (0.1) | NC |
| Others | 41 (6.0) | 698 (10.3) | 0.51 (0.33 to 0.78) |
ILD, interstitial lung disease; NC, not calculated.